Alvotech Advances Partnerships To Take Pipeline Global
By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.
You may also be interested in...
A proposal to merge with a special purpose acquisition company, in a move that will deliver longstanding plans for a public listing, has led biosimilars specialist Alvotech to discuss its ambitions and goals for its pipeline of seven biosimilar candidates.
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.